title: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
abstract: Recent studies suggest that the endocannabinoid system modulates feeding. Despite the existence of central mechanisms for the regulation of food intake by endocannabinoids, evidence indicates that peripheral mechanisms may also exist. To test this hypothesis, we investigated (1) the effects of feeding on intestinal anandamide accumulation; (2) the effects of central (intracerebroventricular) and peripheral (intraperitoneal) administration of the endocannabinoid agonist anandamide, the synthetic cannabinoid agonist R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrol[1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone monomethanesulfonate (WIN55,212-2), and the CB1-selective antagonist N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR141716A) on food intake in rats; and (3) the effects of sensory deafferentation on the modulation of feeding by cannabinoids. Food deprivation produced a sevenfold increase in anandamide content in the small intestine but not in the brain or stomach. Refeeding normalized intestinal anandamide levels. Peripheral but not central administration of anandamide or WIN55,212-2 promoted hyperphagia in partially satiated rats. Similarly, peripheral but not central administration of SR141716A reduced food intake. Capsaicin deafferentation abolished the peripheral effects of both cannabinoid agonists and antagonists, suggesting that these agents modulate food intake by acting on CB1 receptors located on capsaicin-sensitive sensory terminals. Oleoylethanolamide, a noncannabinoid fatty ethanolamide that acts peripherally, prevented hyperphagia induced by the endogenous cannabinoid anandamide. Pretreatment with SR141716A enhanced the inhibition of feeding induced by intraperitoneal administration of oleoylethanolamide. The results reveal an unexpected role for peripheral CB1 receptors in the regulation of feeding.
authors.affiliation: University Institute of Drug Dependencies, Department of Psychobiology, University Complutense of Madrid, Madrid 28223, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Gómez
authors.forename: Miguel
authors.initials: M
authors.lastname: Navarro
authors.forename: Belén
authors.initials: B
authors.lastname: Ferrer
authors.forename: José M
authors.initials: JM
authors.lastname: Trigo
authors.forename: Ainhoa
authors.initials: A
authors.lastname: Bilbao
authors.forename: Ignacio
authors.initials: I
authors.lastname: Del Arco
authors.forename: Andrea
authors.initials: A
authors.lastname: Cippitelli
authors.forename: Felice
authors.initials: F
authors.lastname: Nava
authors.forename: Daniele
authors.initials: D
authors.lastname: Piomelli
authors.forename: Fernando
authors.initials: F
authors.lastname: Rodríguez de Fonseca
mesh_terms: D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology; D001095:Arachidonic Acids / Q000378:metabolism / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D048588:Benzoxazines; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators; D002211:Capsaicin / Q000494:pharmacology; D003714:Denervation; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004435:Eating / Q000187:drug effects; D063388:Endocannabinoids; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology*; D005753:Gastric Mucosa / Q000378:metabolism; D006963:Hyperphagia / Q000139:chemically induced / Q000188:drug therapy; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D007421:Intestine, Small / Q000378:metabolism; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D019301:Oleic Acid / Q000494:pharmacology; D009829:Oleic Acids; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000077285:Rimonabant; D012528:Satiety Response / Q000187:drug effects
chemical_list: D001095:Arachidonic Acids; D048588:Benzoxazines; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D009025:Morpholines; D009281:Naphthalenes; D009829:Oleic Acids; C440229:Oleylethanolamide; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D019301:Oleic Acid; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D000077285:Rimonabant; D002211:Capsaicin; C078814:anandamide